Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
A phase 2/3 trial of Vibegron in childhood cancers, run by Urovant Sciences GmbH, now recruiting.
Overview
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC is a phase 2/3 interventional study registered as NCT05491525 by Urovant Sciences GmbH, with 71 participants planned, started 2022-10-12 and due to reach its primary completion in 2030-03. Interventions recorded: Vibegron.
Similar pages
not linked directly; found by shared links- TrialPK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Shares Childhood cancers (all types) and the tag pipeline.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Childhood cancers (all types) and the tag pipeline.
- TrialStudy to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shares Childhood cancers (all types) and the tag pipeline.
- TrialCEB-01 in Paediatrics With Locally Resectable Abdominal Tumours
Shares Childhood cancers (all types) and the tag pipeline.
- TrialInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Shares Childhood cancers (all types) and the tag pipeline.
- TrialAlpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Shares Childhood cancers (all types) and the tag pipeline.
- TrialA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Shares Childhood cancers (all types) and the tag pipeline.
- TrialA Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Shares Childhood cancers (all types) and the tag pipeline.